I own PSTI but rarely post anymore
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
http://seekingalpha.com/article/1276811-the-stem-cell-revolution-can-jump-start-your-portfolio-jason-kolbert
FONAR's Subsidiary Acquires Business Managing 12 UPRIGHT(R) MRI Scanners
http://ih.advfn.com/p.php?pid=nmona&article=56597696
FONAR Reports 12 Straight Quarters of Net Income From Operations and Six Straight Quarters of Profitability Greater Than $1.5
http://ih.advfn.com/p.php?pid=nmona&article=56292763
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
http://seekingalpha.com/article/1276811-the-stem-cell-revolution-can-jump-start-your-portfolio-jason-kolbert
Harris & Harris Group Reports Financial Statements as of December 31, 2012
http://ih.advfn.com/p.php?pid=nmona&article=56760547
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
http://seekingalpha.com/article/1276811-the-stem-cell-revolution-can-jump-start-your-portfolio-jason-kolbert
Mesoblast Completes A$170m Private Placement
http://ih.advfn.com/p.php?pid=nmona&article=56720148
What It Really Costs To Mine Gold: The Yamana Gold Edition
http://seekingalpha.com/article/1262161-what-it-really-costs-to-mine-gold-the-yamana-gold-edition?source=yahoo
It states in this document that the VDK codecs are based on 1994 patents have expired?
https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=86920
So what exactly does TMMI own right now (other than the name "TRUDEF")?
Could another company use the expired patents and create fractal video compression?
Orphan Drugs: 'Rare' Opportunities To Make Money
http://www.forbes.com/sites/edsilverman/2012/08/23/orphan-drugs-rare-opportunities-to-make-money/
peer reviews now online...
http://www.pluristem.com/technology/peer-reviewed-articles/
House Backs Renewal of Biodefense Initiatives; Bill Proceeds to Obama
http://www.nti.org/gsn/article/house-backs-biodefense-renewal-bill-proceeds-obama/
House Backs Renewal of Biodefense Initiatives; Bill Proceeds to Obama
http://www.nti.org/gsn/article/house-backs-biodefense-renewal-bill-proceeds-obama/
OH Yea :)
Back to lurking
Any thoughts on PSTI options? In the money June $2.50 look interesting to anyone at .90 bid 1.05 ask?
JBII is a GEYI - Alphakat copycat IMHO. If JBI were honest about not re-inventing the wheel they could have bought 4 GEYI-Alphacat processors (before Covanta made the agreement exclusive) and used their special secret catalyst (which is probably not any better than Dr Koch's patented catalyst) and would have been making 2000 liters of high grade diesel fuel an hour for the last year (instead of spending 15 million in development costs). GEYI's immediate fate is in Covanta's hands and there is the risk that they will not continue but after three years of progress, I like the odds at this time.
Deals that have no obligation from "partners" except that they purchase fuel products at a discount to market prices will do nothing to validate the efficiency of any system.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=63011318
Myself, I see value in a GEYI Alphakat KDV system that is production ready and was selected and paid for by the largest waste to energy company in the US for extensive year long testing. The GEYI stock should respond if Covanta ends up giving the greenlight to 600 Alphacat KDV 500 systems and we should learn the results anytime now.
Satcon® Appoints New Chief Financial Officer
Satcon Technology Corp. (MM) (NASDAQ:SATC)
Today : Friday 13 May 2011
Satcon Technology Corporation® (NASDAQ CM:SATC), a leading provider of utility scale power conversion solutions for the renewable energy market, today announced that its Board of Directors has appointed Aaron M. Gomolak to be its Executive Vice President, Chief Financial Officer and Treasurer effective May 11, 2011, replacing Donald R. Peck.
Mr. Gomolak has been working at Satcon in several roles since May of 2008, both as a consultant handling the company’s financials from 2008 to 2010, and most recently as the company’s Senior Vice President of Global Operations.
Steve Rhoades, Satcon’s President and Chief Executive Officer said, “I want to thank Don Peck for his important contributions to our company over the past year which enabled us to successfully recapitalize.”
“I am pleased to have Aaron Gomolak as part of my leadership team as we take the company to the next level of growth and profitability,” continued Mr. Rhoades. “As we intensify our expansion into new markets and geographies with our industry leading utility solar solutions, Aaron’s deep international experience will be instrumental to Satcon’s long-term success.”
Prior to Satcon, Mr. Gomolak was with Advanced Energy Industries, Inc., a publicly traded company providing power conversion products to renewable energy markets, serving as their Vice President of Finance and Corporate Controller.
About Satcon
Satcon Technology Corporation is a leading provider of utility-grade power conversion solutions for the renewable energy market, enabling the industry's most advanced, reliable, and proven clean energy alternatives. For more than ten years, Satcon has designed and delivered advanced power conversion products that enable large-scale producers of renewable energy to convert the clean energy they produce into grid-connected efficient and reliable power. To learn more about Satcon, please visit http://www.Satcon.com.
Safe Harbor
Statements made in this document that are not historical facts or which apply prospectively are forward-looking statements that involve risks and uncertainties. These forward-looking statements are identified by the use of terms and phrases such as "will," "intends," "believes," "expects," "plans," "anticipates" and similar expressions. Investors should not rely on forward looking statements because they are subject to a variety of risks and uncertainties and other factors that could cause actual results to differ materially from the company's expectation. Additional information concerning risk factors is contained from time to time in the company's SEC filings, including its Annual Report on Form 10-K and other periodic reports filed with the SEC. Forward-looking statements contained in this press release speak only as of the date of this release. Subsequent events or circumstances occurring after such date may render these statements incomplete or out of date. The company expressly disclaims any obligation to update the information contained in this release.
Long Term Prospects Remain Bright for Rare Earth Explorers
Rare Element Res Ltd Ordinary Shares (Canada) (AMEX:REE)
Today : Thursday 12 May 2011
Rare Earth Explorers are getting crushed in the markets this week after North America's largest Rare Earth miner, Molycorp posted first quarter earnings nowhere near the analyst consensus. Although rare earth metal prices are surging due to favorable demand conditions, there are currently no separation facilities for the all-important "heavy" rare earths outside of China, leaving North American explorers to struggle for revenues. The Bedford Report examines the Rare Earth Elements Industry and provides research reports on Molycorp, Inc. (NYSE: MCP) and Rare Element Resources, Inc. (AMEX: REE). Access to the full company reports can be found at:
www.bedfordreport.com/2011-05-MCP
www.bedfordreport.com/2011-05-REE
Colorado-based, Molycorp plans to double production in its California mine by the end of 2013. Molycorp's Mountain Pass mine produces about 3 percent of the world's rare earths from stockpiled concentrate, but the company plans to eventually turn out a quarter of the total supply. Mark Smith, CEO of Molycorp, explains that "unless alternative sources for rare earths are brought on, we are going to have a very significant shortfall in terms of how much material is available versus how much we need."
The Bedford Report releases regular market updates on the industrial metals sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.
Canada-based, Rare Element Resources has a 100% interest in the Bear Lodge property located in northeast Wyoming. A recent economic assessment shows that the deposit has an internal rate of return of nearly 40 percent. According to REE, exploration potential continues to be "excellent" as recent geological surveys claim Bear Lodge "contains one of the largest deposits of disseminated rare-earth elements in North America."
The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer
Contact:
The Bedford Report
Covanta Holding Corporation to Present at the Barclays Capital Clean Solutions Conference
Covanta (NYSE:CVA)
Today : Thursday 12 May 2011
Covanta Holding Corporation (NYSE: CVA) is scheduled to participate in the Barclays Capital Clean Solutions Conference on Wednesday, May 18, 2011. Executive Vice President and CFO Sanjiv Khattri will be speaking at 8:30 a.m. Eastern Time.
The presentation materials will be made available on the day of the conference and can be accessed through the Investor Information - Presentations section of the Covanta Holding Corporation website at www.covantaenergy.com. The recorded webcast link will be made available and posted on Covanta's website by Tuesday, May 24, 2011.
About Covanta
Covanta Energy Corporation is an internationally recognized owner and operator of large-scale Energy-from-Waste and renewable energy projects and a recipient of the Energy Innovator Award from the U.S. Department of Energy's Office of Energy Efficiency and Renewable Energy. Covanta's 44 Energy-from-Waste facilities provide communities with an environmentally sound solution to their solid waste disposal needs by using that municipal solid waste to generate clean, renewable energy. Annually, Covanta's modern Energy-from-Waste facilities safely and securely convert approximately 20 million tons of waste into 9 million megawatt hours of clean renewable electricity and more than 9 billion pounds of steam that are sold to a variety of industries. For more information, visit www.covantaenergy.com.
SOURCE Covanta Holding Corporation
GEYI is the US partner for Alphakat and here is an interesting comparison of certain claims made from another publicly traded competitor JBII that has also been mentioned on this board:
GEYI Alphakat vs JBII AlphaKat KDV 500: JBI Global: Advantage:
Volume claims > 1kg plastic into 1 liter diesel 1kg plastic into 1 liter diesel similar
Speed claims > 1 ton organic waste in one hour 1800lb plastic in one hour similar
Modular > Finished product since 2007 Working on it? KDV
Fuel quality claims > High quality diesel High quality diesel/gas similar (depends on feedstock)
System cost claims* > Several Million Euros 587k?* JBI-KDV?*
Patents > 70+ Worldwide Claims 5 in progress? KDV
Field Experience > Dr. Christian Koch - 20+ years John Bordynuik - 2? years? KDV
Market Cap > GEYI (as partner) 15 million? JBII 180 million? ? (subject to change daily)
*The JBI, inc cost claims were not stated as a "for sale" price but rather were claims of what it cost the company to build a system and it is unclear if that price includes shipping, delivery and setup to a remote location. No build costs are available for the Alphakat system and multiple system discount could possibly change the cost per unit so accurate cost comparisons are incomplete (ie JBI does not appear interested in selling their processor for $587k even without the "secret" catalyst).
Both companies claim their catalyst can break the carbon chains where they choose and customize the type of fuel output using low temperatures and no pressure.
http://siliconinvestor.advfn.com/readmsg.aspx?msgid=27346149
Alphakat has a turbine that is run from the diesel it produces and it has no stack and the JBI system uses some of the "off-gas" to heat the processor and captures the remainder.
Another difference is that JBII is showing interest in mostly high carbon waste plastic and also claims to produce #2 diesel and some gasoline while KDV 500 claims to process all types of organic waste (including waste plastic) and has been optimized to produce high caloric value #2 grade diesel fuel (if testing is successful, Covanta has agreed to pay for ASTM diesel fuel certification). Note: it is not disputed that the carbon content in the feedstock determines the percentage of the fuel output. Because Alphakat can accept all organic waste they also offer an additional module to reduce the sulfur content if the clients waste stream contains a lot of sulfur.
Alphakat and JBI Global operate under different business models so cost comparisons are limited because JBI stated it intends to receive considerably higher percentage of the fuel produced so when looking at long range plan, the KDV unit could be considered more cost effective to a prospective customer depending on their projected price of diesel fuel and useful years of operation.
It should be noted that the KDV 500 has been operating in in the USA (Massachusetts) at the Covanta plant under a contract with GEYI since June 2010 and Covanta - Alphakat GEYI has also has been given funding from the U.S. Army to develop a portable waste to energy system. If testing is successful, the contract calls for Covanta to purchase 600 KDV500's and it was estimated up front to take 6 months to one year just for testing. Also noteworthy is that the last modification to the agreement (after Covanta had been testing the Alphakat for several months) Covanta has agreed to pay more of the costs for exclusive rights to the Alphakat system in the US). Covnata is the largest waste to energy company in the US and they researched over 200 companies before choosing the Alphakat KDV 500 for testing.
Other issues to consider:
GEYI had used toxic financing (convertible debenture) which had destroyed the stock price over the last few years with dilution as it has been over three years since the original agreement was made with Covanta. GEYI has recently addressed this important issue with an insider group buying back 2/3rds of the remaining convertible debt and a new director spending half a million dollars to buy common stock (at a discount). Insiders have put large amounts of their own money into GEYI common stock over the years. GEYI had commissioned a third party to evaluate the Alphakat system before they invested into a partnership. One caution is that GEYI is a very illiquid stock and there is no guarantee that Covanta will conclude the deal with GEYI.
JBII has also fallen behind the time-line expectations that Mr. Bordynuik expressed in early 2010 (still no simple air permit?) and they have done several PIPE's and is burning through cash and nobody knows where it is going or if all of the technical problems have been solved for sustained long-term production. At least one shareholder is involved with litigation over removing the restriction on their 1.4 million shares of JBII plus an original directer just sold a large percentage of his holdings. JBI Global SEC filings have been problematic with many restatements and accounting firm changes and several subsidies. I am watching closely to see if any large cap companies actually put their own money into a JBI plastic2oil secret catalyst machine as this would add some needed credibility to the claimed cost effectiveness (Covanta searched for two years looking at WTE systems before choosing to test the Alphakat GEYI waste to diesel system and their final conclusions could come at any time).
Deals that have no obligation from "partners" except that they purchase fuel products at a discount to market prices will do nothing to validate the efficiency of the system.
AlphaK.A.T. fights an uphill battle 2005-2008 (English subtitles)
GEYI and JBII are both publicly traded however there are a few private interesting US competitors that you can also research (Note - Every company that wants to acquire the plastic waste stream is a direct competitor to JBI whereas Alphakat will accept the plastic plus all other organic waste):
Envion
Plasco Energy Group
Splainex
InEnTec
Global Resource Corporation
Agilyx
The field of converting waste (especially high carbon plastic) to fuel has become of interest by many companies as the price of crude oil is starting to make it economically attractive. This competition could put price pressure on the waste stream value if the price of oil continues to climb as competitors desire the waste that has the most carbon content. JMHO
Disclaimer: Information is compiled for discussion purposes only and is paraphrased from many online sources and is not guaranteed to be complete, unbiased, current or accurate and is also subject to change without notice and it should not be relied upon to make any investment decisions.
Harris & Harris Group Reports Financial Statements as of March 31, 2011
Harris & Harris Grp., Inc. (MM) (NASDAQ:TINY)
Today : Wednesday 11 May 2011
Harris & Harris Group, Inc. (Nasdaq:TINY), reported today that, as of March 31, 2011, its net asset value and net asset value per share were $146,632,745 and $4.73, respectively.
http://ih.advfn.com/p.php?pid=nmona&article=47615264&symbol=TINY
Satcon Expands Utility-Ready Inverter Portfolio with the Launch of Equinox 625 kW Solution
Satcon Technology Corp. (MM) (NASDAQ:SATC)
Today : Wednesday 11 May 2011
Satcon Technology Corporation® (NASDAQ CM: SATC), a leading provider of utility-scale power conversion solutions for the renewable energy market, today introduced the newest addition to its Equinox™ utility-ready solar solution portfolio, the Satcon Equinox 625 kW. The next-generation Equinox 625 kW inverter, which began shipping in April, joins the 500 kW solution, introduced in June 2010, and is now available in both North America and Europe.
Built upon Satcon's industry-leading PowerGate® Plus inverter family, the world's most widely-deployed large-scale solution, Equinox enhances system-wide energy harvest and solar plant yield, enabling the large-scale solar industry's highest return on investment (ROI). Equinox's advanced utility-ready features enable remote control of real and reactive power, low-voltage ride through and power factor control. The solution supports fast communications, allowing it to be easily integrated into SCADA systems through standardized communication interfaces.
“The next generation of utility-scale solar power requires a comprehensive set of building blocks that delivers the highest levels of system-wide performance, intelligence, and reliability,” said Steve Rhoades, Satcon's President and Chief Executive Officer. “With over two gigawatts of utility-ready solutions sold to date, Satcon has established a leadership position as the solution of choice for the world's most advanced solar installations. Equinox continues this tradition of solution innovation and will enable large-scale PV plant owners and operators to achieve the highest levels of system performance with the lowest Levelized Cost of Energy.”
The Equinox solution features a NEMA 3R/IP54 enclosure with the electronics housed in a NEMA 4/IP65 enclosure, ensuring maximum protection and longevity. It enables the industry's widest thermal operating range with fully-rated performance at temperatures as high as 55° C / 131° F and as low as -20° C / -4° F. With its unparalleled system wide intelligence, Edge MPPT performance optimization and industrial-grade engineering, Satcon's Equinox solutions deliver best-in-class efficiency of 98.5% and offer the highest levels of system-wide performance, uptime and reliability, delivering the industry’s lowest Levelized Cost of Energy (LCOE).
About Satcon
Satcon Technology Corporation is the leading provider of utility-scale power conversion solutions for the renewable energy market, enabling the industry’s most advanced reliable and proven clean energy alternatives. For over 26 years, Satcon has designed and delivered the next generation of efficient energy systems for solar photovoltaic, stationary fuel cells, and energy storage systems. To learn more about Satcon, please visit www.Satcon.com.
Safe Harbor
Statements made in this press release that are not historical facts or which apply prospectively are forward-looking statements that involve risks and uncertainties. These forward-looking statements are identified by the use of terms and phrases such as "will," "intends," "believes," "expects," "plans," "anticipates" and similar expressions. Investors should not rely on forward looking statements because they are subject to a variety of risks and uncertainties and other factors that could cause actual results to differ materially from the company's expectation. Additional information concerning risk factors is contained from time to time in the company's SEC filings, including its Annual Report on Form 10-K and other periodic reports filed with the SEC. Forward-looking statements contained in this press release speak only as of the date of this release. Subsequent events or circumstances occurring after such date may render these statements incomplete or out of date. The company expressly disclaims any obligation to update the information contained in this release.
BIOLASE Receives ASTRUM Award at MDB Capital's Bright Lights Conference 2011
Today : Wednesday 11 May 2011
BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental laser manufacturer and distributor, today announced that it received the ASTRUM Award, presented by MDB Capital Group to Federico Pignatelli, Chairman and CEO, and Dmitri Boutoussov, Vice President of Engineering and Development, at the 2nd annual Bright Lights Conference at the Le Parker Meridien Hotel in New York City. BIOLASE was recognized for its innovation leadership and the development of numerous disruptive technologies measured by the highest Patent Application compound annual growth rate (CAGR) and number of patent applications on file and adjusted for Application Conversion Rate.
"BIOLASE stood out as the top company in its industry with the highest Patent Application CAGR and the highest number of patent applications on file, adjusted for Application Conversion Rate, and we are honored to recognize the Company's achievements in driving IP as an asset class and the impact the Company is making on innovation in America," commented Christopher A. Marlett, CEO of MDB Capital Group.
Pignatelli said, "Providing innovative and disruptive technologies that advance the practice of dentistry and medicine, leading to enhanced outcomes and more comfortable patient experiences, continues to be the focus at BIOLASE. We are especially enthusiastic with our development of a new surgical system to cut human tissue in a biological and atraumatic way. This development could revolutionize the way surgeons perform a broad range of procedures. This award is a testament to those efforts and serves as overdue recognition for our productive and inventive R&D teams in Irvine. We are honored to have been recognized by MDB as it relates to our extensive IP and we look forward to getting many additional technologies to market in the coming years."
BIOLASE was selected from MDB's 2011 group of "Best and Brightest" small-cap companies and advanced as one of the 40 public companies ranking in the 90th percentile for its respective technology leadership from more than 1,500 small-cap companies with granted U.S. patents, as rated by PatentVest, MDB's proprietary IP business intelligence platform. The Bright Lights Conference is the only conference with an exclusive focus on publicly-traded companies with disruptive and market changing IP.
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the World's leading Dental Laser Company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment, products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. Other products under development address ophthalmology and other medical and consumer markets.
For updates and information on laser and Waterlase dentistry, find BIOLASE at http://www.biolase.com, Twitter at http://twitter.com/GoWaterlase, and YouTube at http://www.youtube.com/user/Rossca08.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
For further information, please contact:
Jill Bertotti
Allen & Caron
+1-949-474-4300
Mesoblast deal inspires Teva to swoop on Cephalon
Teva has outbid Valeant in its offer to buy Cephalon, citing interest in Mesoblast's stem cell therapies.
Mesoblast's mesenchymal stem cells under the microscope.
It's an acquisition frenzy as Teva Pharmaceutical Industries has made a US$6.2 billion bid for Cephalon in the wake of the latter's partnership with Australian regenerative medicine company Mesoblast.
The takeover bid trumps a similar bid made by Valeant Pharmaceuticals International, offering a 12 per cent premium on the Valeant's offering. Valeant has subsequently withdrawn its offer.
The Israel-based Teva is offering US$81.50 a share for Cephalon, valuing the company at US$6.8 billion.
Teva cited Cephalon's recent deal with Mesoblast as being one of the elements that inspired the takeover, considering the high-risk but high-reward technology to be very desirable.
Currently Teva's big breadwinner is its multiple sclerosis treatment Copaxone, which comes off patent in 2012. As such, it's on the hunt for the next generation of drugs and biologics, and considers Cephalon-Mesoblast to be a rich source of potential money earners in these areas.
Melbourne-based ChemGenex, which is working to bring its anti-chronic myeloid leukaemia drug, Omapro, to the market, has also been caught up in the takeover shenanigans.
Cephalon was mid-acquisition of ChemGenex when the Valeant and now Teva bids manifest, although ChemGenex insists that the takeover of Cephalon will not disrupt its own deal, which is progressing as planned.
Mesoblast (ASX:MSB) shares lifted another 6.2% in yesterday's trading, to $9.26, and is up nearly 19% over the past 30 days.
ChemGenex is steady at 69c, rising nearly 8% over the month.
http://www.lifescientist.com.au/article/385422/mesoblast_deal_inspires_teva_swoop_cephalon/
________________________
MBLTY is on fire but is competitor PSTI really 25x behind in valuation?
Take a step back and look and what has happened and use some business logic. What we do know is that NIR was winning the lawsuit before the settlement and now gets about 9 million dollars worth of ITRO shares in some mystery formula. These need to be included into the market cap (12 million?). The old convertible notes are canceled. However, why would the new arrangement be kept secret except that Dr Whitney asked for that little favor because he knows the details are not good for shareholders and NIR conceded on this minor point because they want to get their money and the stock price does not matter to them? If it was good news NIR would want the details published to drive the stock price up as they would be the largest shareholder (if they were just holding all their shares like holders of common stock). NIR was winning the lawsuit so why would they settle for anything less than they were getting before?
Remember, Dr. Whitney has never told shareholders in the past whenever bad news was going to hit. Like the surprise RS? Why could the massive RS not have waited until after the lawsuit was finalized and then do the RS to the new NIR shares? Then there is ITRO failing to keep SEC reporting so now they can do PP's to keep going without reporting them?
If Dr Whitney starts some serious buying of Itronics common shares with his own money, then the market might take notice. JMHO
BTW What is Dr Whitney's pay and benefits?
I like the technology but I do not trust Dr Whitney or NIR.
Aastrom CEO Tim Mayleben to Present at the World Stem Cells and Regenerative Medicine Congress 2011 in London
Aastrom Biosciences (NASDAQ:ASTM)
Today : Saturday 7 May 2011
Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded patient-specific cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will present at the World Stem Cells and Regenerative Medicine Congress 2011, which is being held May 9-11, 2011, at Victoria Park Plaza in London, UK.
Mr. Mayleben will participate as a panel speaker for the session entitled, "Autologous vs. Allogeneic: The Great Debate," at 12:10pm (BST) on Monday, May 9, 2011. His presentation, "Launching into Phase III: practical navigation of early clinical challenges," will take place at 2:50pm (BST) on Monday, May 9, 2011.
About Aastrom Biosciences
Aastrom Biosciences is developing expanded patient-specific cellular therapies for use in the treatment of severe, chronic cardiovascular diseases. The company's proprietary cell-processing technology enables the manufacture of mixed-cell therapies expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced its cell therapies into late-stage clinical development, including a planned Phase 3 clinical program for the treatment of patients with critical limb ischemia and two ongoing Phase 2 clinical trials in patients with dilated cardiomyopathy. For more information, please visit Aastrom's website at www.aastrom.com.
This document contains forward-looking statements, including, without limitation, statements concerning clinical trial plans and progress, objectives and expectations, clinical activity timing, intended product development, the performance and contribution of certain individuals and expected timing of collecting and analyzing treatment data, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "potential," "could," "may," or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with clinical trial and product development activities, regulatory approval requirements, competitive developments, and the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. These forward looking statements reflect management's current views and Aastrom does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.
CONTACT: Media and investor contact
Agnes Cao
Berry & Company
212 253-8881
ir@aastrom.com
acao@berrypr.com
DexCom Announces the Sale of 4.7 Million Shares of Common Stock
DexCom, Inc. (Nasdaq: DXCM), today announced the sale of 4.7 million shares of its common stock pursuant to an underwriting agreement with Canaccord Genuity acting as the sole bookrunner. The last reported sale price of our common stock as reported by the Nasdaq Global Market on May 4, 2011 was $16.42 per share.
The Company expects to use the net proceeds from the sale of the shares for working capital and general corporate purposes. Closing of the offering is expected to occur on or about May 10, 2011, subject to customary closing conditions. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 705,000 shares of common stock to cover over-allotments, if any.
The offering is being made pursuant to an effective shelf registration statement. Before you invest, you should read the base prospectus in such shelf registration statement, the prospectus supplement, when available, and other documents we have filed with the Securities and Exchange Commission for more complete information about us and this offering. The offering may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained by sending a request to the offices of Canaccord Genuity, Attn: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110, phone: 617-371-3900. Alternatively, you may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients with diabetes and by healthcare providers in the hospital.
Cautionary Statement Regarding Forward Looking Statements
DexCom is a medical device company with a limited operating history. Successful commercialization and sale of the company's products is subject to numerous risks and uncertainties, including product performance, a lack of acceptance in the marketplace by physicians and patients, the company's inability to manufacture products in commercial quantities at an acceptable cost and quality level, possible delays in the company's development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's quarterly report on Form 10-Q for the period ended March 31, 2011, as filed with the Securities and Exchange Commission on May 3, 2011.
Teva: $500 Million Cost Savings From Cephalon Buy 'Very Conservative'
By Thomas Gryta, Of DOW JONES NEWSWIRES
NEW YORK -(Dow Jones)- Teva Pharmaceutical Industries Ltd.'s (TEVA, TEVA.TV) projected cost savings from its $6.8 billion acquisition of Cephalon Inc. (CEPH) are "very conservative," the generic drug maker's chief financial officer said Wednesday.
Israel-based Teva, which trumped a hostile offer from Valeant Pharmaceuticals International Inc. (VRX) in agreeing to buy Cephalon earlier this week, has projected cost savings of at least $500 million in the third year after the deal. That estimate assumes that Teva makes no changes to its current research and development projects after the deal, even though it plans to conduct a review of those efforts, Teva CFO Eyal Desheh said at a Deutsche Bank conference in Boston.
Desheh reiterated that the cost savings will come from various areas as he provided details on Teva's plans after the deal's expected closing in the third quarter.
About $200 million will come from selling, general and administrative expenses, about $130 million will come from combining the sales and marketing organizations of the two companies, and another $120 million will come from combining research and development infrastructure and management.
The last $50 million in savings will be in manufacturing, Desheh said, because Cephalon'sEurope-based generic arm outsources its production. Teva plans to use excess capacity acquired in its $5 billion deal for German generic-drug company Ratiopharm last year.
-By Thomas Gryta, Dow Jones Newswires; 212-416-2169; thomas.gryta@dowjones.com
(END) Dow Jones Newswires
05-04-111330ET
Copyright (c) 2011 Dow Jones & Company, Inc.
http://www.nasdaq.com/aspx/stock-market-news-story.aspx?storyid=201105041330dowjonesdjonline000480&title=teva500-million-cost-savings-from-cephalon-buy-very-conservative
Delivering High-Performance, Multicore Applications & Efficient Software: ARM Launches Next Generation System Solution for De...
Date : 05/03/2011 @ 8:22AM
Source : Business Wire
Stock : ARM (ARMH)
Quote : 29.12 -2.48 (-7.85%) @ 7:58PM
Today : Tuesday 3 May 2011
ARM today announced the launch of the ARM CoreSight SoC-400, a highly configurable debug and trace solution for complex SoC designs. As multicore products become increasingly common-place, ARM CoreSight SoC-400 provides a system solution to deliver high performance in applications that include mobile phones, tablets, home, wireless infrastructure, networking and gaming. To achieve optimal performance, software developers demand increased visibility within SoC designs. The launch of CoreSight SoC-400 addresses this requirement by providing a powerful, modular debug and trace infrastructure, and tool chain. CoreSight SoC-400 also delivers greater productivity for SoC designers and reduced time to market for new products.
“The demand for complex applications development on multicore SoCs, such as TI’s OMAP™4 platform, continues to increase. ARM's CoreSight can provide advanced debug and trace solutions to aid developers on these platforms," said Stephen Lau, product manager, debug technology, wireless business unit, TI.
CoreSight SoC-400 is based on the ARM CoreSight debug and trace architecture already in use by major silicon suppliers for hardware and software design and optimization. The flexible, modular architecture supports ARM and other industry IP, and is well known in the industry as an established standard with comprehensive tools support.
The introduction of CoreSight SoC-400 extends the CoreSight architecture from existing debug and trace design kits for specific IP, such as ARM Cortex-A9 and ARM Cortex-R4 processors, into a system level solution that provides configurable components and buses which are modular and completely scalable. CoreSight SoC-400 also reduces the time required to deploy debug and trace infrastructure by incorporating the CoreLink™ AMBA Designer tool and packaging IP to deploy more easily. This improves productivity for hardware developers and reduces time to market for new products.
“Until recently debug and trace solutions have been an afterthought in the SoC design process, as basic functionality was acceptable in less demanding applications,” said Mike Dimelow, Marketing Director, Processor Division, ARM. “However, as multicore applications are more common-place, debug and trace solutions become critical to SoC designers and software developers. CoreSight SoC-400 is already providing improved productivity for all parties involved in the design process.”
About CoreSight SoC-400
CoreSight SoC-400 is a comprehensive set of configurable debug & trace components complete with the design tools needed to automate IP stitching and testing. Features of the new solution include complete automated system stitching and test benches and enhanced AMBA® AXI™ Access Port (AXI-AP) functionality, supporting 64 bit address space across the AXI bus. Local and global time stamping is also possible. All components of the CoreSight SoC-400 are supplied with IPXACT descriptors for use with AMBA Designer. For further details on the new features and capabilities of the ARM CoreSight SoC-400 go to http://www.arm.com/products/system-ip/coresight-soc.php
Availability
The ARM CoreSight SoC-400 is licensing to lead partners now, and software support is available in ARM DS-5 tools this month. Initially the ARM CoreSight SoC-400 is available for the ARM Cortex-A15, and then later in 2011 for the entire ARM Cortex processor family.
About ARM
ARM designs the technology that lies at the heart of advanced digital products, from wireless, networking and consumer entertainment solutions to imaging, automotive, security and storage devices. ARM’s comprehensive product offering includes 32-bit RISC microprocessors, graphics processors, video engines, enabling software, cell libraries, embedded memories, high-speed connectivity products, peripherals and development tools. Combined with comprehensive design services, training, support and maintenance, and the company’s broad Partner community, they provide a total system solution that offers a fast, reliable path to market for leading electronics companies. Find out more about ARM by following these links:
* ARM website: http://www.arm.com/
* ARM Connected Community: http://www.arm.com/community/
* ARM Blogs: http://blogs.arm.com/
* ARMFlix on YouTube: http://www.youtube.com/user/ARMflix
* ARM on Twitter:
o http://twitter.com/ARMMobile
o http://twitter.com/ARMCommunity
o http://twitter.com/ARMEmbedded
o http://twitter.com/ARMLowPwr
o http://twitter.com/KeilTools
o http://twitter.com/ARMMultimedia
ARM is a registered trademark of ARM Limited. Cortex, CoreLink, CoreSight, Connected Community and MPCore are trademarks of ARM Limited. All other brands or product names are the property of their respective holders. “ARM" is used to represent ARM Holdings plc; its operating company ARM Limited; and the regional subsidiaries ARM Inc.; ARM KK; ARM Korea Limited.; ARM Taiwan Limited; ARM France SAS; ARM Consulting (Shanghai) Co. Ltd.; ARM Belgium Services BVBA; ARM Germany GmbH; ARM Embedded Technologies Pvt. Ltd.; ARM Norway, AS and ARM Sweden AB
Axion Power™ Announces Date of Its First Quarter 2011 Earnings Release and Conference Call
Date : 05/03/2011 @ 7:30AM
Source : PR Newswire
Stock : Axion Power Intl (AXPW)
Quote : 0.8 -0.02 (-2.44%) @ 4:02PM
Today : Tuesday 3 May 2011
Axion Power International Inc (OTC Bulletin Board: AXPW), announced plans to release its first quarter 2011 results before market on Tuesday, May 17, 2011. The Company will hold a conference call that same day at 11:00 am ET. Interested parties should call 877-485-3104 (domestic) or 201-689-8579 (international), to access the call. You may also access this call via the Internet by visiting the company's website at www.axionpower.com and clicking on the Investors link.
For those who are unavailable to listen to the live broadcast, a replay will be available for seven days and can be accessed by dialing 877-660-6853 (domestic) and 201-612-7415 (international) and using passcode 371881 and account number #356.
About Axion Power International Inc
Axion has developed and patented a next generation energy storage device that won the prestigious Frost & Sullivan Technology Award for North America in the field of lead-acid batteries. According to Frost & Sullivan, Axion's new PbC® batteries have "the potential to revitalize the lead-acid battery industry by breathing new life into an established technology that is not well suited to the requirements of important new applications like hybrid electric vehicles and renewable power."
Axion Power International, Inc. is the industry leader in the field of lead-acid-carbon energy storage technologies. Axion believes this new battery technology is the only class of advanced battery that can be assembled on existing lead-acid battery production lines throughout the world utilizing Axion's proprietary carbon electrodes. Axion's future goal, after filling their plant's lead-carbon battery production capacity, is to become the leading supplier of carbon electrode assemblies for the global lead-acid battery industry.
For more information, visit www.axionpower.com
ContactsAxion Power International IncCharles Trego CFO / Investor Relations(724) 654-9300Allen & Caron IncRudy Barrio (Investors)r.barrio@allencaron.com(212) 691-8087Len Hall (Media)len@allencaron.com (949) 474-4300
SOURCE Axion Power International Inc
Saturday, April 23, 2011 Kleiner Perkins' Bill Joy Ends Silence About EEStor
Source: Masshightech.com
Six years after leading the Kleiner Perkins effort to invest in EEStor, billionaire venture capitalist Bill Joy has finally commented publicly about the investment at the MIT Enterprise Forum of Cambridge this past Thursday evening. During an open Q&A session, an attendee asked about progress at EEStor and Joy spent about five minutes talking about energy storage in general and offered a few thoughts about EEStor in particular. His comments end speculation about whether or not Kleiner Perkins still has an interest in EEStor. They do and Bill Joy is still hopeful they will come through but not ready to cease hedging his bets in the energy storage space.
The fireside chat was hosted by Jason Pontin, editor in chief of Technology Review. Below is rough transcript of the exchange on EEStor. (The audio supplied to me was a little rough in places)
Attendee Question:
Since tomorrow is Earth Day and we're here at MIT, it seems like a unique opportunity to ask you about a portfolio company whose lead researcher got his start here at MIT. I'm talking about Carl Nelson & EEStor. I was wondering if you are happy with the progress to date at EEStor and also if everything pans out there, what is your vision for that company?
Bill Joy:
Well I think. Ok so EEStor is a company that is trying to do a barium titanate giga...I dont know what you call it. It's not hyper super ultra. It's a capacitive energy storage using barium titanate. And it's difficult to do what they are trying to do. And the product isn't out yet.
But if you look at energy storage you know for...what have we typically done? We pump water uphill and let it run downhill. People would propose to maybe make an underground cavern and pressurize it and let the gas out something or you do have flow batteries. You start to go into electrochemistry batteries. Flow batteries or you do lithium ion batteries or sodium ion batteries that we talked about. But ultimately at the end of the day you say, ah, you know, it's volti, right the voltaic cell. This is old stuff. Kind of violates my rule of not doing something that could have been done in the 19th century. I like to think the future isn't gonna just be electrochemistry that we could have solid state energy storage something that's based on you know maybe early 20th century stuff. It could be a quantum effect or some something that lets us have something which is almost perfectly efficient and has some kind of Moore's law effect to it and be very very durable, high power and high energy density.
So you like to have that. And EEStor is an example of something solid state. I always say in investing I prefer solids to liquids and liquids to gases. And we prefer... semiconductors is our favorite kind of solid. So... It's just because we can engineer it. When things sit still, we can engineer their structure more and it's more predictable. And we get access to semiconductor physics which lets us interact with heat and light and all these. There's all of these magical things we can do that came out of say quantum theory. We're gonna....liquid phase or chemistry, you've got free energy bounds on everything you do and you know, it can get messy. .............reactions and materials fall apart. Whereas a solid state, it is the basis of electronics and it can last basically forever. And gases, things move around it's hard to have alot of innovations there.
Energy storage is the same thing. I'd like to see it go from liquid phase chemistry essentially to solid state physics. That would be very desirable. And then you limit cases of energy storage that should be solid state.
Now it is an open question probably whether that...will that transition occur in this decade or the next decade or two decades from now. I'm mean. It's great to have people trying it but it is hard. And so, when we had this list of 25 grand challenges...when we went out looking for things, we didn't think we would find them all. And if we find investable things that are bred(predicated?) on one of those grand challenges, we don't necessarily expect it to work. If the list of 25, 10 of them work, that would be a miracle. Because they are set to be very aspirational. So solid state energy storage would be on the list. And that's an example of an investment that is trying to ...with a improvement on an existing technology essentially because barium titanate is used as a material, common material in capacitors. An improvement on the technology to get there through a very you know controversial way of using that material. So.
You can't always predict....things we can't always predict what materials are going to do. You can't do computational level of algebra. We don't have computer simulations with perfect fidelity for any of these things so we have to go try things. One of our sayings is...we prefer things that work in practice to things that work in theory. It's nice if they work in theory but we can always invent the theory afterwards.
I prefer not to violate the 2nd law of conservation of energy, the standard model. Some things we don't know...any magnetic monopole (?) ....I'm not really interested you know but so we can't always simulate things and we are willing to lose a couple millions dollars to try and see if some effect is plausible or will work ....that we dont have a close form computer simulation. But it's plausible to people trained in the art that it's not.....they can't explain to me on a napkin why it wouldn't work.
Jason Pontin:
For what it's worth, every year, Tech Review chooses the 10 technologies we think are most promising to have some kind of a breakthrough in the near future and Solid state was one of them and EEStor is one of the examples we pointed out.
Bill Joy:
I'd love to find....if someone has another solid state energy state...speculative....it's hard enough to invest in another one of those.
------------------------------------
After the fireside chat, Joy answered questions from a small crowd of people for over an hour.
Question:
So, are you still hopeful about EEStor?
Bill Joy:
Oh yeah. I mean these things are hard so there is always a chance they won't work. But we're very uh......We'll see. I don't know anything that isn't in the press.
Question: ....a person team somebody that already may already have a solution that hasn't been discovered, is that something you think is possible? Like a crowdsouring...somewhere in world that's working....
Bill Joy:
It doesn't tend to work that way. It proceeds from somebody who has deep expertise in a domain who acquires interdisciplinary collaborators. Thats a better formula. There are no child prodigies in these fields that involve physics and chemistry.
You really just have....you mentioned Carl Nelson he is like 90 years old an MIT PHD material scientist, who is one of the inventors under EEStor. If you don't have someone like Carl. I mean you ask Carl, tell me something about halfnium. Carl will talk to you for 15 minutes about halfnium. He knows something about every element in the periodic table. He can tell you off the top of his head what its crystal forms are and alot of interesting properties. I mean you have to be intimate with the periodic table to do this kind of stuff. You have know... .you really have to have had a career. With somebody like that, he's probably the oldest founder I ever backed. But you just have dinner with him and you realize he really understands what he is doing with materials.
Now what they are proposing to do is wild. And there's lots of reasons in which some of these things could fail to be commercialized. I'm not saying whether it's worked or not and if we've announced it or not, I'm just saying it's hard. What they're trying to do...obviously, it's took years...to get....since they....first....it's not easy to do these things. So...but the worthwhile things usually are hard and they always take longer
http://bariumtitanate.blogspot.com/2011/04/kleiner-perkins-bill-joy-ends-silence.html